Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Viatris Inc. (NASDAQ: VTRS) and Mapi Pharma announced the presentation of recent clinical findings regarding GA Depot at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston from April 22-27, 2023. The pivotal Phase III clinical trial analyzes the efficacy and safety of GA Depot, a long-acting glatiramer acetate for treating relapsing forms of multiple sclerosis (RMS). Viatris emphasizes its commitment to improving healthcare access for MS patients through innovative solutions. The poster session details include research results to be presented on April 24, 2023, from 5:30 to 6:30 p.m. EST.
Viatris is dedicated to providing high-quality medicines globally, with a portfolio of over 1,400 approved molecules across various therapeutic areas.
Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2023 financial results on May 8, 2023, before the markets open. CEO Scott Smith, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same day to discuss the results. Investors can access the live webcast at investor.viatris.com or by calling 800-579-2543. A replay will also be available on their website. Founded in November 2020, Viatris focuses on providing access to medicines globally. The company operates in over 165 countries and boasts a portfolio of more than 1,400 approved medicines across a wide range of therapeutic areas.